BridgeMD
New treatment option for NSCLC Stage IV Without EGFR/ALK Mutation
Official title A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
ClinicalTrials.gov ID: NCT06947694
What this study is testing
What is chemotherapy + PD-1 inhibitors?
chemotherapy + PD-1 inhibitors is an investigational medicine, being studied as a potential treatment for nsclc stage iv without egfr/alk mutation.
Also referred to as Radiotherapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patient must meet all of the following to be enrolled in this study:
- Non-small cell lung cancer diagnosed initially through pathological histology.
- There are 3-6 metastatic lesions.
- No brain metastasis or the lesions are stable.
- Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names).
You likely can't join if
- Patients with any of the following criteria are not eligible for enrollment in this study:
- Those with severe dysfunction of vital organs (heart, liver, kidney).
- Those accompanied by other malignant tumors.
- Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months.
- Those with a history of mental illness.
- And other situations in which the researchers deem it inappropriate for the people to participate in the study.
See the full eligibility criteria
- Patient must meet all of the following to be enrolled in this study:
- Non-small cell lung cancer diagnosed initially through pathological histology.
- There are 3-6 metastatic lesions.
- No brain metastasis or the lesions are stable.
- Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET genes. Note: The above English terms are all gene names).
- ECOG (Eastern Cooperative Oncology Group) score: 0-1 point, with an expected, survival period of more than 3 months.
- Aged between 18 and 75 years old.
- Evaluated by PET-CT (including FDG and FMISO, not mandatory).
- No contraindications for immunotherapy and radiotherapy.
- The informed consent form has been signed.
- Patients with any of the following criteria are not eligible for enrollment in this study:
- Those with severe dysfunction of vital organs (heart, liver, kidney).
- Those accompanied by other malignant tumors.
- Those with uncontrolled heart diseases or having experienced a myocardial infarction within the past six months.
- Those with a history of mental illness.
- And other situations in which the researchers deem it inappropriate for the people to participate in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.